Omega-3 Fatty Acids (EPA/DHA) for Ulcerative Colitis (UC)
CMixed results in maintaining UC remission. Some meta-analyses show modest benefit; others show no significant effect. EPA may be more beneficial than DHA.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Domega\u002D3\u002Dfatty\u002Dacids\u0026condition\u003Dibd\u002Dulcerative\u002Dcolitis';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
The Bottom Line
Mixed results in maintaining UC remission. Some meta-analyses show modest benefit; others show no significant effect. EPA may be more beneficial than DHA.
Key Study Findings
Review
Diet in Ulcerative Colitis: A Narrative Review of Its Role in Pathogenesis and Treatment.
Dose: None
vs: None
Outcome: None
Effect: None
None
Population: patients with ulcerative colitis
Review
Are there Effective Vegan-Friendly Supplements for Optimizing Health and Sports Performance? a Narrative Review.
Dose: None
vs: None
Outcome: Athletic performance and nutritional optimization
Effect: None
None
Population: Vegan athletes (narrative review)
Review
From Evidence to Practice: A Narrative Framework for Integrating the Mediterranean Diet into Inflammatory Bowel …
Dose: None
vs: None
Outcome: None
Effect: None
None
Population: None
Review
Gut microbiome-centric nutritional strategies in inflammatory bowel disease: Modulating dysbiosis for therapeutic benefit.
Dose: None
vs: None
Outcome: IBD microbiota modulation and immune regulation
Effect: None
None
Population: IBD patients (review of nutritional interventions)
Review
Association between Omega-3 fatty acids and autoimmune disease: Evidence from the umbrella review and Mendelian …
Dose: None
vs: None
Outcome: Colitis severity
Effect: None
None
Population: Crohn's disease patients
Other
Interaction between diet and genetics in patients with inflammatory bowel disease.
Dose: None
vs: None
Outcome: Diet-genetics interaction in IBD
Effect: None
None
Population: IBD patients (editorial commentary)
Key Statistics
8
Studies
1000
Participants
↔
Mixed
C
Grade
Referenced Papers
Digestive diseases and …
2026
1 citations
Nutrients
2025
9 citations
Semergen
2025
4 citations
Current nutrition reports
2025
3 citations
Autoimmunity reviews
2024
12 citations
World journal of …
2024
Metabolites
2023
13 citations
Association between dietary acid load and the odds of ulcerative colitis: a case-control study.
Other
Scientific reports
2023
1 citations
Nutrients
2022
66 citations
Nutrients
2022
61 citations
Journal of medicinal …
2022
8 citations
Foods (Basel, Switzerland)
2021
96 citations
Nutrients
2021
27 citations
Scientific reports
2020
56 citations
Therapeutic advances in …
2020
21 citations
Redox modulatory protective effects of ω-3 fatty acids rich fish oil against experimental colitis.
Other
Toxicology mechanisms and …
2019
33 citations
Nutrients
2019
24 citations
Gastroenterology clinics of …
2018
67 citations
International journal of …
2017
143 citations
Medical principles and …
2017
45 citations
Ugeskrift for laeger
2017
Annals of gastroenterology
2016
80 citations
European journal of …
2016
79 citations
Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn's Disease and Ulcerative Colitis.
Review
Current pharmaceutical design
2016
32 citations
Clinics in dermatology
2016
19 citations
World journal of …
2014
36 citations
World journal of …
2014
25 citations
Alimentary pharmacology & …
2013
128 citations
Nutritional modulators of ulcerative colitis: clinical efficacies and mechanistic view.
Systematic Review
World journal of …
2013
56 citations
The British journal …
2012
145 citations
Dietary supplements for established atopic eczema.
Meta-Analysis
The Cochrane database …
2012
130 citations
World journal of …
2012
113 citations
Frontline gastroenterology
2012
20 citations
Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature.
Systematic Review
The American journal …
2011
946 citations
Inflammatory bowel diseases
2011
195 citations
Nutrition in clinical …
2011
1 citations
JRSM short reports
2010
11 citations
Inflammatory bowel diseases
2008
77 citations
The Cochrane database …
2007
118 citations
Journal of food …
2007
49 citations
Nutrition (Burbank, Los …
2003
189 citations
Nutricion hospitalaria
2003
Journal of the …
2002
2016 citations
Nutrition (Burbank, Los …
2000
64 citations
Drugs
1998
99 citations
The American journal …
1998
84 citations
Bailliere's clinical gastroenterology
1997
26 citations
Langenbecks Archiv fur …
1995
3 citations
The American journal …
1992
260 citations
The American journal …
1991
2278 citations
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Commonly Used Dosages
- general:
- 1,000-2,000 mg combined EPA/DHA per day
- ibdsupport:
- 2,000-4,000 mg/day combined EPA/DHA (higher EPA ratio may be more beneficial)
Upper limit: 3,000 mg/day combined EPA/DHA (FDA GRAS limit)
Dosages Studied in Research
| Dosage | Duration | Effect | N |
|---|---|---|---|
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Neutral | -- |
| None | -- | Neutral | -- |
| 95% | -- | Mixed | 124 |
| 95% | -- | Mixed | -- |
Best taken: With meals containing fat for better absorption
Safety & Side Effects
Reported Side Effects
- ⚠ Fishy aftertaste and burping
- ⚠ Mild gastrointestinal discomfort (nausea, diarrhea)
- ⚠ Potential increased bleeding time at very high doses (>3 g/day)
- ⚠ May lower blood pressure slightly
Known Interactions
- ● Anticoagulants and antiplatelet drugs (may increase bleeding risk at high doses)
- ● Blood pressure medications (additive hypotensive effect)
- ● Orlistat (may reduce omega-3 absorption)
- ● Cyclosporine (fish oil may reduce cyclosporine nephrotoxicity but monitor levels)
Tolerable upper intake: 3,000 mg/day combined EPA/DHA (FDA GRAS limit)
Always consult your healthcare provider before starting any supplement.
Frequently Asked Questions
Does Omega-3 Fatty Acids (EPA/DHA) help with Ulcerative Colitis (UC)?
Based on 8 studies with 1,000 participants, there is limited but promising evidence that Omega-3 Fatty Acids (EPA/DHA) may support Ulcerative Colitis (UC) management. Our evidence grade is C (Some Evidence).
How much Omega-3 Fatty Acids (EPA/DHA) should I take for Ulcerative Colitis (UC)?
Studies have used various dosages. A commonly studied range is 1,000-2,000 mg combined EPA/DHA per day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Omega-3 Fatty Acids (EPA/DHA)?
Reported side effects may include Fishy aftertaste and burping, Mild gastrointestinal discomfort (nausea, diarrhea), Potential increased bleeding time at very high doses (>3 g/day), May lower blood pressure slightly. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Omega-3 Fatty Acids (EPA/DHA) and Ulcerative Colitis (UC)?
We rate the evidence as Grade C (Some Evidence). This rating is based on 8 peer-reviewed studies with 1,000 total participants. The overall direction of effect is mixed.
Related Evidence
Other ingredients for Ulcerative Colitis (UC)
Omega-3 Fatty Acids (EPA/DHA) for other conditions
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. The products and information on this website are not intended to diagnose, treat, cure, or prevent any disease. The evidence grades presented are based on our analysis of published peer-reviewed research and do not constitute medical advice. Always consult your healthcare provider before starting any supplement regimen.